Matches in SemOpenAlex for { <https://semopenalex.org/work/W3152604037> ?p ?o ?g. }
- W3152604037 endingPage "1907" @default.
- W3152604037 startingPage "1907" @default.
- W3152604037 abstract "Minimal residual disease (MRD) detection is established routine practice for treatment stratification in leukemia and used for treatment optimization in adult lymphomas. Minimal disease studies in childhood non-Hodgkin lymphomas are challenged by stratified treatment in different subtypes, high cure rates, low patient numbers, limited initial tumor material, and early progression. Current clinical applications differ between the subtypes. A prognostic value of minimal disseminated disease (MDD) could not yet be clearly established for lymphoblastic lymphoma using flow cytometry and PCR-based methods for T-cell receptor (TCR) or immunoglobulin (IG) rearrangements. MYC–IGH fusion sequences or IG rearrangements enable minimal disease detection in Burkitt lymphoma and -leukemia. An additional prognostic value of MDD in Burkitt lymphoma and early MRD in Burkitt leukemia is implicated by single studies with risk-adapted therapy. MDD and MRD determined by PCR for ALK-fusion transcripts are independent prognostic parameters for patients with ALK-positive anaplastic large cell lymphoma (ALCL). They are introduced in routine clinical practice and used for patient stratification in clinical studies. Early MRD might serve as an endpoint for clinical trials and for guiding individual therapy. Validation of MDD and MRD as prognostic parameters is required for all subtypes but ALCL. Next-generation sequencing-based methods may provide new options and applications for minimal disease evaluation in childhood lymphomas." @default.
- W3152604037 created "2021-04-26" @default.
- W3152604037 creator A5007763268 @default.
- W3152604037 creator A5044107490 @default.
- W3152604037 creator A5077889850 @default.
- W3152604037 creator A5082332900 @default.
- W3152604037 date "2021-04-15" @default.
- W3152604037 modified "2023-09-26" @default.
- W3152604037 title "Minimal Disease Monitoring in Pediatric Non-Hodgkin’s Lymphoma: Current Clinical Application and Future Challenges" @default.
- W3152604037 cites W1485389706 @default.
- W3152604037 cites W1501225775 @default.
- W3152604037 cites W1562875840 @default.
- W3152604037 cites W1582146330 @default.
- W3152604037 cites W1794321307 @default.
- W3152604037 cites W1986385592 @default.
- W3152604037 cites W1988355083 @default.
- W3152604037 cites W1991349095 @default.
- W3152604037 cites W1993428519 @default.
- W3152604037 cites W1997647834 @default.
- W3152604037 cites W2016085357 @default.
- W3152604037 cites W2019108602 @default.
- W3152604037 cites W2020094108 @default.
- W3152604037 cites W2029846811 @default.
- W3152604037 cites W2032972450 @default.
- W3152604037 cites W2038586807 @default.
- W3152604037 cites W2039212724 @default.
- W3152604037 cites W2043586607 @default.
- W3152604037 cites W2047043493 @default.
- W3152604037 cites W2050133210 @default.
- W3152604037 cites W2062032144 @default.
- W3152604037 cites W2062308740 @default.
- W3152604037 cites W2067221216 @default.
- W3152604037 cites W2074651724 @default.
- W3152604037 cites W2079517811 @default.
- W3152604037 cites W2083898003 @default.
- W3152604037 cites W2084734126 @default.
- W3152604037 cites W2090643222 @default.
- W3152604037 cites W2095871627 @default.
- W3152604037 cites W2107692941 @default.
- W3152604037 cites W2107853162 @default.
- W3152604037 cites W2133908319 @default.
- W3152604037 cites W2134766521 @default.
- W3152604037 cites W2137816642 @default.
- W3152604037 cites W2139047632 @default.
- W3152604037 cites W2140755317 @default.
- W3152604037 cites W2142519069 @default.
- W3152604037 cites W2143297413 @default.
- W3152604037 cites W2143502805 @default.
- W3152604037 cites W2148743957 @default.
- W3152604037 cites W2162244898 @default.
- W3152604037 cites W2165401507 @default.
- W3152604037 cites W2167771975 @default.
- W3152604037 cites W2299785708 @default.
- W3152604037 cites W2320580975 @default.
- W3152604037 cites W2398469716 @default.
- W3152604037 cites W2460040011 @default.
- W3152604037 cites W2509865886 @default.
- W3152604037 cites W2534116795 @default.
- W3152604037 cites W2537125730 @default.
- W3152604037 cites W2551589138 @default.
- W3152604037 cites W2557582684 @default.
- W3152604037 cites W2579829632 @default.
- W3152604037 cites W2579884965 @default.
- W3152604037 cites W2587199293 @default.
- W3152604037 cites W2742652175 @default.
- W3152604037 cites W2758939411 @default.
- W3152604037 cites W2763231168 @default.
- W3152604037 cites W2764246936 @default.
- W3152604037 cites W2765626054 @default.
- W3152604037 cites W2795755595 @default.
- W3152604037 cites W2805583487 @default.
- W3152604037 cites W2888203943 @default.
- W3152604037 cites W2888723857 @default.
- W3152604037 cites W2915674725 @default.
- W3152604037 cites W2920942906 @default.
- W3152604037 cites W2972643862 @default.
- W3152604037 cites W2981687944 @default.
- W3152604037 cites W2986273560 @default.
- W3152604037 cites W2989961700 @default.
- W3152604037 cites W3001173747 @default.
- W3152604037 cites W3007903876 @default.
- W3152604037 cites W3016696556 @default.
- W3152604037 cites W3031235513 @default.
- W3152604037 cites W3031891765 @default.
- W3152604037 cites W3046021472 @default.
- W3152604037 cites W3087892739 @default.
- W3152604037 cites W3108113721 @default.
- W3152604037 cites W3134569209 @default.
- W3152604037 cites W3134747655 @default.
- W3152604037 doi "https://doi.org/10.3390/cancers13081907" @default.
- W3152604037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8071445" @default.
- W3152604037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33921029" @default.
- W3152604037 hasPublicationYear "2021" @default.
- W3152604037 type Work @default.
- W3152604037 sameAs 3152604037 @default.
- W3152604037 citedByCount "6" @default.
- W3152604037 countsByYear W31526040372021 @default.
- W3152604037 countsByYear W31526040372022 @default.